Diagnosis and management of ST elevation myocardial infarction: A review of the recent literature and practice guidelines

Mount Sinai Journal of Medicine

Volumn 73, Issue 1, 2006, Pages 469-481

  Hahn, Sigrid A ^a   Chandler, Charles ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Diagnosis; Fibrinolysis; Myocardial infarction; PCI; Reperfusion; Review; STEMI; Therapy; Treatment

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 10A; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NITRIC ACID DERIVATIVE; PLACEBO; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR; RETEPLASE; STREPTOKINASE; TENECTEPLASE; THROMBIN; THROMBOXANE A2; TICLOPIDINE; TIROFIBAN; UROKINASE;

ADJUVANT THERAPY; ANGIOPLASTY; BLEEDING; BLOOD TOXICITY; BLOOD TRANSFUSION; BOLUS INJECTION; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COCHRANE LIBRARY; CORONARY ARTERY BYPASS GRAFT; DATA ANALYSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; ELECTROCARDIOGRAPHY; EVIDENCE BASED MEDICINE; EVIDENCE BASED PRACTICE; FEASIBILITY STUDY; FIBRINOLYSIS; FOLLOW UP; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH PROGRAM; HEART INFARCTION; HEART LEFT BUNDLE BRANCH BLOCK; HEART MUSCLE REPERFUSION; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HEART REINFARCTION; HEART REPOLARIZATION; HEART RIGHT BUNDLE BRANCH BLOCK; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOTENSION; INFORMATION RETRIEVAL; INTERNET; LONG TERM CARE; MAINTENANCE DRUG DOSE; MEDICAL DOCUMENTATION; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; MONOTHERAPY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PUBLIC HEALTH SERVICE; PUBLICATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETREATMENT; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; ST SEGMENT DEPRESSION; ST SEGMENT ELEVATION; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TACHYCARDIA; TREATMENT INDICATION; TREATMENT PLANNING;

BUNDLE-BRANCH BLOCK; ELECTROCARDIOGRAPHY; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES;

EID: 32044440074     PISSN: 00272507     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004; 110:e82-e292.
2. Van de Werf F, Ardissino D, Betriu A, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003; 24(1):28-66.
3. Menon V, Harrington RA, Hochman JS, et al. Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:549S-575S.
4. Clinical policy: critical issues in the evaluation and management of adult patients presenting with suspected acute myocardial infarction or unstable angina. American College of Emergency Physicians. Ann Emerg Med 2000; 35(5):521-525.
5. Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol 2000; 36:2056-2063.
6. American Heart Association. Heart Disease and Stroke Statistics - 2004 Update. Dallas, Texas: American Heart Association; 2003.
7. Alpert JS, Thygesen K, Antman E, et al. Myocardial infarction redefined - a consensus document of the Joint European Society of Cardiology/ American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36:959-969.
8. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994; 343(8893):311-322; erratum in: Lancet 1994; 343(8899):742.
9. Brieger D, Eagle KA, Goodman SG, et al. Acute coronary syndromes without chest pain, an underdiagnosed and under-treated high-risk group: insights from the Global Registry of Acute Coronary Events. Chest 2004; 126:461-469.
10. Canto JG, Shlipak MG, Rogers WJ, et al. Prevalence, clinical characteristics, and mortality among patients with myocardial infarction presenting without chest pain. JAMA 2000; 283:3223-3229.
11. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 2000; 283:2941-2947.
12. Angeja BG, Gibson CM, Chin R, et al. Predictors of door-to-balloon delay in primary angioplasty. Am J Cardiol 2002: 89:1156-1161.
13. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per to Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet 1986; 1:397-402.
14. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. J Am Coll Cardiol 1988; 12:3A-13A.
15. Wellens HJ. Acute myocardial infarction and left bundle-branch block - can we lift the veil? N Engl J Med 1996; 334:528-529.
16. Sgarbossa EB, Pinski SL, Barbagelata A, et al. Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. GUSTO-1 (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators. N Engl J Med 1996; 334:481-487.
17. Gula LJ, Dick A, Massel D. Diagnosing acute myocardial infarction in the setting of left bundle branch block: prevalence and observer variability from a large community study. Coron Artery Dis 2003; 14:387-393.
18. Sokolove PE, Sgarbossa EB, Amsterdam EA, et al. Interobserver agreement in the electrocardiographic diagnosis of acute myocardial infarction in patients with left bundle branch block. Ann Emerg Med 2000; 36:566-571.
19. Shah A, Wagner GS, Green CL, et al. Electrocardiographic differentiation of the ST-segment depression of acute myocardial injury due to the left circumflex artery occlusion from that of myocardial ischemia of nonocclusive etiologies. Am J Cardiol 1997; 80:512-513.
20. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361:13-20.
21. Magid DJ, Calonge BN, Rumsfeld JS, et al. Relation between hospital primary angioplasty volume and mortality for patients with acute MI treated with primary angioplasty vs thrombolytic therapy. JAMA 2000; 284:3131-3138.
22. Zahn R, Schiele R, Schneider S, et al. Decreasing hospital mortality between 1994 and 1998 in patients with acute myocardial infarction treated with primary angioplasty but not in patients treated with intravenous thrombolysis. Results from the pooled data of the Maximal Individual Therapy in Acute Myocardial Infarction (MITRA) Registry and the Myocardial Infarction Registry (MIR). J Am Coll Cardiol 2000; 36:2064-2071.
23. Translation of clinical trials into practice: a European population-based study of the use of thrombolysis for acute myocardial infarction. European Secondary Prevention Study Group. Lancet 1996; 347:1203-1207.
24. Lillie-Blanton M, Maddox TM, Rushing O, et al. Disparities in cardiac care: rising to the challenge of Healthy People 2010. J Am Coll Cardiol 2004; 44:503-508.
25. Buiatti E, Barchielli A, Marchionni N, et al. Determinants of treatment strategies and survival in acute myocardial infarction: a population-based study in the Florence district, Italy: results of the acute myocardial infarction Florence registry (AMI-Florence). Eur Heart J 2003; 24:1195-1203.
26. Vermeer F, Oude Ophuis AJ, vd Berg EJ, et al. Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility study. Heart 1999; 82(4):426-431.
27. Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of coronary angioplasty with fibrinolysic therapy in acute myocardial infarction. N Engl J Med 2003; 349:733-742.
28. Zijlstra F. Angioplasty vs thrombolysis for acute myocardial infarction: a quantitative overview of the effects of interhospital transportation. Eur Heart J 2003; 24:21-23.
29. Jacobs AK. Primary angioplasty for acute myocardial infarction - is it worth the wait? N Engl J Med 2003; 349:798-800.
30. Aversano T, Aversano LT, Passamani E, et al. Thrombolysic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: a randomized controlled trial. JAMA 2002; 287(15):1943-1951.
31. An international randomized trial comparing four thrombolysic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993; 329(10):673-682.
32. Carney RJ, Murphy GA, Brandt TR, et al. Randomized angiographic trial of recombinant tissue-type plasminogen activator (alteplase) in myocardial infarction. RAAMI Study Investigators. J Am Coll Cardiol 1992; 20:17-23.
33. Bleich SD, Adgey AA, McMechan SR, Love TW. An angiographic assessment of alteplase: double-bolus and front-loaded infusion regimens in myocardial infarction. DouBLE Study Investigators. Double Bolus Lysis Efficacy. Am Heart J 1998; 136(4 Pt 1):741-748.
34. Bode C, Smalling RW, Berg G, et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators. Circulation 1996; 94:891-898.
35. A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. N Engl J Med 1997; 337:1118-1123.
36. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators. Lancet 1999; 354:716-722.
37. Gore JM, Granger CB, Simoons ML, et al. Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. Circulation 1995; 92(10):2811-2818.
38. Berkowitz SD, Granger CB, Pieper KS, et al. Incidence and predictors of bleeding after contemporary thrombolysic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators. Circulation 1997; 95:2508-2516.
39. Boersma E, Maas AC, Deckers JW, et al. Early thrombolysic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996; 348:771-775.
40. Morrison LJ, Verbeek PR, McDonald AC, et al. Mortality and prehospital thrombolysis for acute myocardial infarction: a meta-analysis. JAMA 2000; 283:2686-2692.
41. Pedley DK, Bissett K, Connolly EM, et al. Prospective observational cohort study of time saved by prehospital thrombolysis for ST elevation myocardial infarction delivered by paramedics. BMJ 2003; 327:22-26.
42. Morrow DA, Antman EM, Sayah A, et al. Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: results of the Early Retavase-Thrombolysis in Myocardial Infarction (ER-TIMI) 19 trial. J Am Coll Cardiol 2002; 40(1):71-77.
43. Bonnefoy E, Lapostolle F, Leizorovicz A, et al. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet 2002; 360:825-829.
44. Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. TIMI. II A results. The TIMI Research Group. JAMA 1988; 260:2849-2858.
45. Simoons ML, Arnold AE, Betriu A, et al. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet 1988; 1:197-203.
46. Herrmann HC, Moliterno DJ, Ohman EM, et al. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial. J Am Coll Cardiol 2000; 36:1489-1496.
47. Kastrati A, Mehilli J, Schlotterbeck K, et al. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial. JAMA 2004; 291:947-954.
48. Fernandez-Aviles F, Alonso JJ, Castro-Beiras A, et al. Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST segment elevation (GRACIA-1): a randomised controlled trial. Lancet 2004; 364(9439):1045-1053.
49. Verheugt FW. Lyse now, stent later: the grace of GRACIA. Lancet 2004; 364:1014-1015.
50. Widimsky P, Budesinsky T, Vorac D, et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial - PRAGUE-2. Eur Heart J 2003; 24:94-104.
51. Steg PG, Bonnefoy E, Chabaud S, et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation 2003; 108:2851-2856.
52. Zahn R, Schiele R, Gitt AK, et al. Impact of prehospital delay on mortality in patients with acute myocardial infarction treated with primary angioplasty and intravenous thrombolysis. Am Heart J 2001; 142(1):105-111.
53. Braunwald E. Heart disease: a textbook of cardiovascular medicine. 6th ed., W.B. Saunders Company; 2001.
54. Eisenberg PR. Role of heparin in coronary thrombolysis. Chest 1992; 101:131S-139S.
55. Gurbel PA, Serebruany VL, Shustov AR, et al. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries. J Am Coll Cardiol 1998; 31:1466-1473.
56. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2:349-360.
57. Popma JJ, Berger P, Ohman EM, et al. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:576S-599S.
58. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346:957-966.
59. Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 1998; 98:734-741.
60. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344:1895-1903.
61. Montalescot G, Borentain M, Payot L, et al. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST segment elevation myocardial infarction: a meta-analysis. JAMA 2004; 292:362-366.
62. Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001; 357:1905-1914.
63. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (Assent)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358(9282): 605-613.
64. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997; 337:447-452.
65. Wallentin L, Goldstein P, Armstrong PW, et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 2003; 108:135-142.
66. Freemantle N, Cleland J, Young P, et al. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318:1730-1737.
67. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet 1994; 343:1115-1122.
68. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995; 345:669-685.